Search

Your search keyword '"Laura Burunat"' showing total 2 results
Start Over Author "Laura Burunat" Topic immunology
2 results on '"Laura Burunat"'

1. Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants

Author

Javier García-Pérez, Alberto M. Borobia, Mayte Pérez-Olmeda, Antonio Portolés, Luis Castaño, Magdalena Campins-Artí, María Jesús Bertrán, Mercedes Bermejo, José Ramón Arribas, Andrea López, Ana Ascaso-del-Rio, Eunate Arana-Arri, Inmaculada Fuentes Camps, Anna Vilella, Almudena Cascajero, María Teresa García-Morales, María Castillo de la Osa, Carla Pérez Ingidua, David Lora, Paloma Jiménez-Santana, Silvia Pino-Rosa, Agustín Gómez de la Cámara, Erick De La Torre-Tarazona, Esther Calonge, Raquel Cruces, Cristóbal Belda-Iniesta, José Alcamí, Jesús Frías, Antonio J. Carcas, Francisco Díez-Fuertes, Lucía Díaz García, Elena Ramírez García, Enrique Seco Meseguer, Stefan Mark Stewart Balbàs, Alicia Marín Candón, Irene García García, Mikel Urroz Elizalde, Paula de la Rosa, Marta Sanz García, Cristina López Crespo, Vega Mauleón Martínez, Raquel de Madariaga Castell, Laura Vitón Vara, Rocío Prieto-Pérez, Emilio Vargas-Castrillón, Leonor Laredo, Ouhao Zhu-Huang, Teresa Iglesias, Natale Imaz-Ayo, Susana Meijide, Aitor García de Vicuña, Ana Santorcuato, Iraide Exposito, Sara de Benito, Alazne Bustinza, Mikel Gallego, Dolores García-Vázquez, Ana Belén de la Hoz, Gustavo Pérez-Nanclares, Josu Aurrekoetxea, Ines Urrutia, Rosa Martínez-Salazar, Janire Orcajo, Begoña Calvo, June Corcuera, Olaia Velasco, Anibal Aguayo, Xavier Martínez-Gómez, Susana Otero-Romero, Lluis Armadans, Blanca Borras-Bermejo, Oleguer Parés, Sonia Uriona, José Ángel Rodrigo Pendás, Cesar Llorente, José Santos, Laia Pinós, Lina Camacho, Judith Riera, Carla Sans, Antonia Agustí, Carmen Altadill, Carla Aguilar Blancafort, Gisela Gili Serrat, Aitana Plaza, Anna Feliu Prius, Maria Margarita Torrens, Esther Palacio, Gloria Torres, Julia Calonge, Elena Ballarin Alins, Eulàlia Pérez-Esquirol, Lourdes Vendrell Bosch, Marta Aldea, Eugènia Mellado, Ma Ángeles Marcos, Marta Tortajada, Lourdes E. Barón-Mira, Laura Granés, Sulayman Lazaar, Sara Herranz, Montserrat Malet, Sebastiana Quesada, Anna Llupià, Victoria Olivé, Antoni Trilla, Begoña Gómez, Elisenda González, Sheila Romero, Francisco Javier Gámez, Cristina Casals, Laura Burunat, Juan José Castelló, Patricia Fernández, Josep Lluís Bedini, Jordi Vila, Juan Carlos Hurtado, Isabel Jado, Giovanni Fedele, Concepción Perea, Mónica González, Isabel Grajera, María Ángeles Murillo, Pilar Balfagón, Irene Díaz-Marín, and Gema González-Pardo

Subjects
Immunology, Immune response, Science
Abstract

Summary: CombiVacS study has demonstrated a strong immune response of the heterologous ChAdOx1-S/BNT162b2 vaccine combination. The primary outcomes of the study were to assess the humoral immune response against SARS-CoV-2, 28 days after a third dose of a mRNA vaccine, in subjects that received a previous prime-boost scheme with ChAdOx1-S/BNT162b2. Secondary outcomes extended the study to 3 and 6 months. The third vaccine dose of mRNA-1273 in naive participants previously vaccinated with ChAdOx1-S/BNT162b2 regimen reached higher neutralizing antibodies titers against the variants of concern Delta and BA.1 lineage of Omicron compared with those receiving a third dose of BNT162b2 at day 28. These differences between BNT162b2 and mRNA-1273 arms were observed against the ancestral variant G614 at day 90. Suboptimal neutralizing response was observed against BQ.1.1, XBB.1.5/XBB.1.9, and JN.1 in a relevant proportion of individuals 180 days after the third dose, even after asymptomatic Omicron breakthrough infections. EudraCT (2021-001978-37); ClinicalTrials.gov (NCT04860739).

Published
2024
Full Text
View/download PDF

2. Effect of Intranodally Administered Dendritic Cell-Based HIV Vaccine in Combination With Pegylated Interferon α-2a on Viral Control Following ART Discontinuation: A Phase 2A Randomized Clinical Trial

Author

Lorna Leal, Elvira Couto, Sonsoles Sánchez-Palomino, Núria Climent, Irene Fernández, Laia Miralles, Yolanda Romero, Tania González, Maria José Maleno, Blanca Paño, Judit Pich, Carlos Nicolau, José Maria Gatell, Montserrat Plana, Felipe García, the DCV3-RISVAC04 Study Group, Carmen Hurtado, Laura Burunat, Joan Albert Arnaiz, Rafael Salvador, Elisabet Farré, Berta Torres, Constanza Lucero, Montserrat Laguno, María Martínez-Rebollar, Ana González-Cordón, John Rojas, Alexy Inciarte, Lorena de la Mora, Josep Mallolas, Esteban Martínez, José Luis Blanco, Unai Perpiñá, Josep Canals, Raquel Martín, Florencia Echeverry, Cristina Xufré, Cristina Rovira, Marta Sala, and Amparo Tricas

Subjects
Adult, Male, medicine.medical_specialty, Time Factors, dendritic cell, T-Lymphocytes, Immunology, Alpha interferon, combined strategy, HIV Infections, Placebo, Gastroenterology, Polyethylene Glycols, law.invention, Double-Blind Method, Randomized controlled trial, law, Internal medicine, Outcome Assessment, Health Care, medicine, Humans, Immunology and Allergy, interferon alpha, Prospective Studies, HIV vaccine, Interferon alfa, AIDS Vaccines, business.industry, Drug Administration Routes, ELISPOT, Interferon-alpha, ATI, Dendritic Cells, Middle Aged, RC581-607, Combined Modality Therapy, Clinical Trial, Recombinant Proteins, CD4 Lymphocyte Count, Clinical trial, Anti-Retroviral Agents, Withholding Treatment, therapeutic vaccine, Lymph Nodes, Immunologic diseases. Allergy, business, Viral load, medicine.drug
Abstract

IntroductionFunctional cure has been proposed as an alternative to lifelong antiretroviral therapy and therapeutic vaccines represent one of the most promising approaches.Materials and MethodsWe conducted a double-blind randomized placebo-controlled clinical trial to evaluate the safety, immunogenicity, and effect on viral dynamics of a therapeutic vaccine produced with monocyte-derived dendritic cells (MD-DC) loaded with a high dose of heat-inactivated autologous (HIA) HIV-1 in combination with pegylated interferon alpha 2a (IFNα-2a) in people with chronic HIV-1.ResultsTwenty-nine male individuals on successful ART and with CD4+ ≥450 cells/mm3 were randomized 1:1:1:1 to receive three ultrasound-guided inguinal intranodal immunizations, one every 2 weeks: (1) vaccine ~107 MD-DC pulsed with HIA-HIV-1 (1010 HIV RNA copies) (n = 8); (2) vaccine plus three doses of 180 mcg IFNα-2a at weeks 4–6 (n = 6); (3) placebo = saline (n = 7); and (4) placebo plus three doses of 180 mcg IFNα-2a (n = 8). Thereafter, treatment was interrupted (ATI). Vaccines, IFNα-2a, and the administration procedures were safe and well tolerated. All patients’ viral load rebounded during the 12-week ATI period. According to groups, changes in viral set-point between pre-ART and during ATI were not significant. When comparing all groups, there was a tendency in changes in viral set-point between the vaccine group vs. vaccine + IFNα-2a group (>0.5log10p = 0.05). HIV-1-specific T-cell responses (IFN-ƴ Elispot) were higher at baseline in placebo than in the vaccine group (2,259 ± 535 vs. 900 ± 200 SFC/106 PBMC, p = 0.028). A significant difference in the change of specific T-cell responses was only observed at week 4 between vaccine and placebo groups (694 ± 327 vs. 1,718 ± 282 SFC/106 PBMC, p = 0.04). No effect on T-cell responses or changes in viral reservoir were observed after INFα-2a administration.DiscussionResults from this study show that intranodally administered DC therapeutic vaccine in combination with IFNα-2a was safe and well-tolerated but had a minimal impact on viral dynamics in HIV-1 chronic infected participants.Clinical Trial Registration(www.ClinicalTrials.gov), identifier NCT02767193

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results